Background: Invasive group A streptococcal (iGAS) disease is notifiable in Israel and all isolates are analyzed at the Streptococcus national reference center.
Methods: During 2019-2021 a total of 1,696 iGAS isolates (blood-51.3%, wounds-29.4%) were assigned into 113 emm types. Emerging clusters were further analyzed for antimicrobial susceptibility and whole genome sequencing. Sequences were analyzed for phylogeny, resistance and virulence determinants.
Results: An initial reduction in total iGAS incidence was observed during the first year of the COVID-19 pandemic (Figure 1), followed by the emergence and expansion of two previously rare types: emm74.0, emm77.0 (Figure 2).
The yearly incidence of iGAS during 2019-2021 was 6.8, 5.3 and 6.2 cases/100,000. The predominant emm types were emm106.0 (N=147, 8.7%), emm1.0 (N=124, 7.3%), emm77.0 (N=110, 6.5%), emm81.2 (N=90, 5.3%) and emm89.0 (N=87, 5.1%).
During 2021, emm77.0 was the cause of 110 cases, (6.4%) and became the leading type, followed by emm74.0 (54 cases, 3.2%). WGS-based phylogeny confirmed clonality (≤3 and ≤2 allelic differences, respectively) among geographically dispersed cases. emm77.0 and emm74.0 cases were mostly male (69%, 83%) adults ≥18 years (93%, 93%). Investigation indicated risk factors for emm74.0 were drug use, and homelessness. Both types were resistant to tetracycline (tet(M)). The emm77.0 strains were additionally resistant to trimethoprim/sulfamethoxazole (dfrG). The Israeli emm74.0 ST-120 sequence was distinct compared to an ongoing Canadian ST-120 outbreak profile (111 allelic differences).
Conclusions: The simultaneous emergence of two resistant and previously rare lineages may reflect selective advantage following reduction of respiratory transmission of GAS.